Skip to Main Content

Ovid Therapeutics’ experimental drug for a devastating rare disease proved no better than placebo in a pivotal clinical trial, the company said Tuesday, a bitter disappointment for families dealing with the untreatable condition.

The study enrolled 97 children with Angelman syndrome, a rare genetic disorder that causes seizures and severe cognitive impairment, and randomized them to receive either Ovid’s drug, OV101, or placebo. After 12 weeks, a daily oral dose of OV101 was no better than placebo at improving the symptoms of Angelman, which include impaired sleep, inability to speak, delayed motor development, and intellectual disability.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!